(Q36686037)

15 August 2017

1 reference

title

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. (English)

1 reference

15 August 2017

6

Georg Schett

1 reference

15 August 2017

Michael Knoflach

3

1 reference

ORCID Public Data File 2021

author name string

Stefan Kiechl

1

1 reference

15 August 2017

Philipp Werner

2

1 reference

15 August 2017

Martin Furtner

4

1 reference

15 August 2017

Johann Willeit

5

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Expert Review of Cardiovascular Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

801-811

1 reference

Inflammation in coronary artery disease: potential role for immunomodulatory therapy

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Autoimmune and inflammatory mechanisms in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

The complexities of skeletal biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Soluble RANKL and risk of nontraumatic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Inflammatory Mediators as Essential Elements in Bone Remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin and diabetic macroangiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Increased levels of osteoprotegerin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Recent advances in multifactorial regulation of vascular calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteogenic regulation of vascular calcification: an early perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Association of osteoprotegerin with human abdominal aortic aneurysm progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Apoptosis in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Plasma osteoprotegerin is associated with mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (S

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin gene polymorphisms in men with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

The long and the short of bone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

Toll-like Receptor 4 Polymorphisms and Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.6.801

21 January 2018

Identifiers

DOI

10.1586/14779072.4.6.801

1 reference

15 August 2017

1 reference